425 related articles for article (PubMed ID: 27649950)
1. Immunoexpression of p53 in cutaneous and subcutaneous leiomyosarcomas.
Fernandez-Flores A; Monteagudo C
Ann Diagn Pathol; 2016 Oct; 24():25-9. PubMed ID: 27649950
[TBL] [Abstract][Full Text] [Related]
2. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
[TBL] [Abstract][Full Text] [Related]
3. P16, Ki67, P53, and WT1 Expression in Uterine Smooth Muscle Tumors: An Adjunct in Confirming the Diagnosis of Malignancy in Ambiguous Cases.
Delgado B; Dreiher J; Braiman D; Meirovitz M; Shaco-Levy R
Int J Gynecol Pathol; 2021 May; 40(3):257-262. PubMed ID: 32897968
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous leiomyomas and leiomyosarcomas: an immunohistochemical study with p53.
Fernandez-Flores A
Rom J Morphol Embryol; 2010; 51(2):295-8. PubMed ID: 20495746
[TBL] [Abstract][Full Text] [Related]
5. Immunoexpression of progesterone receptor, epithelial growth factor receptor and galectin-3 in uterine smooth muscle tumors.
Soltan MM; Albasry AM; Eldosouky MK; Abdelhamid HS
Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):7-12. PubMed ID: 29729689
[TBL] [Abstract][Full Text] [Related]
6. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.
Allen MM; Douds JJ; Liang SX; Desouki MM; Parkash V; Fadare O
Int J Clin Exp Pathol; 2015; 8(3):2795-801. PubMed ID: 26045786
[TBL] [Abstract][Full Text] [Related]
7. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
Mittal K; Demopoulos RI
Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
[TBL] [Abstract][Full Text] [Related]
8. Answer to "Immunoexpression of p53 in cutaneous and subcutaneous leiomyosarcomas".
Fernandez-Flores A; Monteagudo C
Ann Diagn Pathol; 2017 Feb; 26():75-76. PubMed ID: 27806883
[No Abstract] [Full Text] [Related]
9. A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors.
Lee CH; Turbin DA; Sung YC; Espinosa I; Montgomery K; van de Rijn M; Gilks CB
Mod Pathol; 2009 Dec; 22(12):1519-31. PubMed ID: 19734847
[TBL] [Abstract][Full Text] [Related]
10. Intraoperative Frozen Section Biopsy of Uterine Smooth Muscle Tumors: A Clinicopathologic Analysis of 112 Cases With Emphasis on Potential Diagnostic Pitfalls.
Lok J; Tse KY; Lee EYP; Wong RWC; Cheng ISY; Chan ANH; Leung CKL; Cheung ANY; Ip PPC
Am J Surg Pathol; 2021 Sep; 45(9):1179-1189. PubMed ID: 34074809
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis in the diagnosis of uterine myometrial smooth muscle tumors.
Stănescu AD; Nistor E; Sajin M; Stepan AE
Rom J Morphol Embryol; 2014; 55(3 Suppl):1129-36. PubMed ID: 25607395
[TBL] [Abstract][Full Text] [Related]
12. Smooth muscle tumors of uncertain malignant potential and leiomyosarcomas of the uterus: MR findings.
Tanaka YO; Nishida M; Tsunoda H; Okamoto Y; Yoshikawa H
J Magn Reson Imaging; 2004 Dec; 20(6):998-1007. PubMed ID: 15558559
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors: Implications for Immunotherapy.
Shanes ED; Friedman LA; Mills AM
Am J Surg Pathol; 2019 Jun; 43(6):792-801. PubMed ID: 31009388
[TBL] [Abstract][Full Text] [Related]
14. Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors.
Gökaslan H; Türkeri L; Kavak ZN; Eren F; Sişmanoğlu A; Ilvan S; Durmuşoğlu F
Gynecol Obstet Invest; 2005; 59(1):36-40. PubMed ID: 15377824
[TBL] [Abstract][Full Text] [Related]
15. [Practical diagnostic aspects of uterine leiomyosarcoma in the context of the 2020 WHO classification].
Horn LC; Hiller GGR; Mayr D; Schmoeckel E; Höhn AK
Pathologe; 2022 May; 43(3):196-201. PubMed ID: 35412039
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of smooth muscle myosin, smooth muscle actin, h-caldesmon, and calponin in the diagnosis of myofibroblastic and smooth muscle lesions of skin and soft tissue.
Perez-Montiel MD; Plaza JA; Dominguez-Malagon H; Suster S
Am J Dermatopathol; 2006 Apr; 28(2):105-11. PubMed ID: 16625070
[TBL] [Abstract][Full Text] [Related]
18. [Smooth muscle neoplasms of the uterus--a 51 cases study].
Wang M; Xu Y; Zhang T
Zhonghua Bing Li Xue Za Zhi; 1996 Oct; 25(5):263-5. PubMed ID: 9388867
[TBL] [Abstract][Full Text] [Related]
19. Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features.
Maltese G; Fontanella C; Lepori S; Scaffa C; Fucà G; Bogani G; Provenzano S; Carcangiu ML; Raspagliesi F; Lorusso D
Oncology; 2018; 94(1):1-6. PubMed ID: 28869928
[TBL] [Abstract][Full Text] [Related]
20. Pathologic considerations of uterine smooth muscle tumors.
Prayson RA; Hart WR
Obstet Gynecol Clin North Am; 1995 Dec; 22(4):637-57. PubMed ID: 8786875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
